News25/Ratings1
News · 26 weeks32-40%
2025-10-262026-04-19
Mix2290d
- Insider10(45%)
- Other6(27%)
- SEC Filings5(23%)
- Earnings1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Asadorian Raffi4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Aslam Shakil4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Dasu Badri N4 - TALPHERA, INC. (0001427925) (Issuer)
- SECSEC Form EFFECT filed by Talphera Inc.EFFECT - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form 424B7 filed by Talphera Inc.424B7 - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
- PRTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.Poster Presentation 1Title: A Randomized, Placebo-Controlled, Multi-Center Study Of The Safety And Efficacy Of Niyad In Patients Undergoing Continuous Renal Replacement Therapy (CRRT) Who Cannot Tolerate Heparin Or Are At A Higher Risk of Ble
- SECSEC Form 10-K filed by Talphera Inc.10-K - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- PRTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePreviously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 millionAll 12 clinical study sites now able to enroll patients to support an expected study completion in 2026Cash and investments of $20.4 million at December 31, 2025Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ETSAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter
- PRTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT). To register, click here.The experts will discuss their experience with CRRT, the anticoagulan
- INSIDERSEC Form 4 filed by Large owner Nantahala Capital Management, Llc4 - TALPHERA, INC. (0001427925) (Issuer)
- SECTalphera Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - TALPHERA, INC. (0001427925) (Filer)
- PRTalphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational TrialEnrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr
- INSIDERCHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERChief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERChief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERChief Financial Officer Asadorian Raffi covered exercise/tax liability with 3,891 shares and bought $36,554 worth of Commom Stock (45,000 units at $0.81), increasing direct ownership by 87% to 88,323 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECSEC Form 424B7 filed by Talphera Inc.424B7 - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form EFFECT filed by Talphera Inc.EFFECT - TALPHERA, INC. (0001427925) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)